A high incidence of vertebral fracture in women with breast cancer.
Because treatment for breast cancer may adversely affect skeletal metabolism, we investigated vertebral fracture risk in women with non-metastatic breast cancer. The prevalence of vertebral fracture was similar in women at the time of first diagnosis to that in an age-matched sample of the general population. The incidence of vertebral fracture, however, was nearly five times greater than normal in women from the time of first diagnosis [odds ratio (OR), 4.7; 95% confidence interval (95% CI), 2.3-9.9], and 20-fold higher in women with soft-tissue metastases without evidence of skeletal metastases (OR, 22.7; 95% CI, 9.1-57.1). We conclude that vertebral fracture risk is markedly increased in women with breast cancer.
Kanis
J A
JA
WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK.
McCloskey
E V
EV
Powles
T
T
Paterson
A H
AH
Ashley
S
S
Spector
T
T
D000284:Administration, Oral; D000367:Age Factors; D000368:Aged; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary; D001943:Breast Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D004002:Clodronic Acid / Q000008:administration & dosage*; D015331:Cohort Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D016017:Odds Ratio; D010024:Osteoporosis / Q000150:complications* / Q000517:prevention & control; D016103:Spinal Fractures / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D013629:Tamoxifen / Q000008:administration & dosage
D018712:Analgesics, Non-Narcotic; D018931:Antineoplastic Agents, Hormonal; D004002:Clodronic Acid; D013629:Tamoxifen